Stock listing

Frankfurt:34D DiaSorin S.p.A. Aktie

German listing (Frankfurt) of DiaSorin S.p.A. · home listing Milan:DIA

Follow DiaSorin S.p.A. into a list and get an email when it puts out news.

Share price · FWB:34D

€80.26 EUR -0.22 (-0.3%)

Close on Oct 30, 2026

Day range
€80.26 – €80.26 EUROct 30, 2026
Market cap
€3.95B EURAt the close on Oct 30, 2026 · price × 49.27M shares outstanding
DiaSorin S.p.A. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:DSRLF$88.21 USD—2$88.21$88.21$88.21—Close on Oct 16, 2026
Frankfurt:34D€80.26 EUR-0.22 (-0.3%)—€80.26€80.26€80.26€80.48Close on Oct 30, 2026
Dusseldorf:34D€79.86 EUR-0.64 (-0.8%)—€80.12€80.64€79.86€80.50Close on Oct 30, 2026
Stuttgart:34D€80.68 EUR+1.10 (+1.4%)—€80.66€80.78€79.66€79.58Close on Oct 27, 2026
Ticker
Frankfurt:34D
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

DiaSorin S p A Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay

May 19, 2026

DiaSorin S p A Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President

May 4, 2026

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024

Mar 20, 2026

DiaSorin S p A signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform

Mar 19, 2026

DiaSorin S p A introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN

Feb 24, 2026

DiaSorin S p A submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver

Feb 3, 2026

DiaSorin S p A has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL

Jan 29, 2026

DiaSorin S p A signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel

Jan 26, 2026

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer.

Jan 22, 2026

DiaSorin S p A receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform

Dec 30, 2025

All DiaSorin S.p.A. news

Decks

DiaSorin S.p.A. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
13 in the last 12 months · 22 in all · newest May 19, 2026 · oldest 2025
Decks
115 decks · latest Sep 30, 2026

Where DiaSorin S.p.A. is listed

ListingExchangeCountryCurrency
Milan:DIA · Home listingMilanItalyEUR
gettex:34DgettexGermanyEUR
VIE:DIASViennaAustriaEUR
LS Exchange:A0MTB2LS ExchangeGermanyEUR
LSIN:0GZXLSINUnited KingdomEUR
Lang & Schwarz:A0MTB2Lang & SchwarzGermanyEUR
OTC:DSRLFOTCUnited StatesUSD
Aquis:DIAMAquisUnited KingdomEUR
Tradegate:34DTradegateGermanyEUR
Aquis:DIAMAquisUnited KingdomEUR
Frankfurt:34D · This pageFrankfurtGermanyEUR
Hanover:34DHanoverGermanyEUR
BIVA:DIA1NBIVAMexicoMXN
BMV:DIA1NBMVMexicoMXN
Dusseldorf:34DDusseldorfGermanyEUR
Hamburg:34DHamburgGermanyEUR
Munich:34DMunichGermanyEUR
Stuttgart:34DStuttgartGermanyEUR
Turquoise:DIAMTurquoiseUnited KingdomEUR

Log in to ask 6ix AI your own questions about DiaSorin S.p.A.